DDIs with perpetrator compounds that induce CYP2C
| Victim | Perpetrator | % Change AUC | Victim Dose (Oral) | Perpetrator Dose (Oral) | References |
|---|---|---|---|---|---|
| Tolbutamide CYP2C9 in vivo probe | Aprepitant | −30.8 | 500 mg | 125/80 mg (3 days) | (Shadle et al., 2004) |
| Tolbutamide CYP2C9 in vivo probe | Rifampicin | −62.5 | 500 mg | 600 mg (14 days) | (Adams et al., 2005) |
| Tolbutamide CYP2C9 in vivo probe | Ritonavir | −50.5 | 500 mg | 200-400 mg (average of 14 days) | (Kirby et al., 2011) |
| (S)-warfarin CYP2C9 in vivo probe | Bosentan | −29.3 | 26 mg | 500 mg (10 days) | (Weber et al., 1999) |
| (S)-warfarin CYP2C9 in vivo probe | Dalcetrapib | −14 | 5 mg of racemic warfarin | 900 mg (7 days) | (Derks et al., 2009) |
| (S)-warfarin CYP2C9 in vivo probe | Rifampicin | −74.4 | 0.75 mg/kg | 300 mg (14 days) | (Heimark et al., 1987) |
| (S)-warfarin CYP2C9 in vivo probe | Ritonavir | −24.3 | 10 mg | 100 mg (14 days) | (Morcos et al., 2013) |
| Repaglinide CYP2C8 in vivo probe | Rifampicin | −79.6 | 4 mg | 600 mg (7 days) | (Bidstrup et al., 2004) |
| Repaglinide CYP2C8 in vivo probe | Flucloxacillin | −46.8 | 4 mg | 500 mg (7 days) | (Du et al., 2013) |
| Omeprazole CYP2C19 in vivo probe | Arbamazepine | −39.7 | 20 mg | 400-600 mg/day (3 weeks) | (Bertilsson et al., 1997) |
| Omeprazole CYP2C19 in vivo probe | Efavirenz | −46.4 | 20 mg | 600 mg (17 days) | (Michaud et al., 2012) |
| Omeprazole CYP2C19 in vivo probe | Enzalutamide | −70.5 | 20 mg | 160 mg (85 days) | (Gibbons et al., 2015) |
| Omeprazole CYP2C19 in vivo probe | Rifampicin | −93 | 10 mg | 600 mg (7 days) | (Derungs et al., 2016) |